Abstract
In a clear but measured and scientific dispute against standard practice today, the American Society of Addiction Medicine (ASAM) has called for an end to the standardization of doses of buprenorphine for opioid use disorder (OUD). The recommendations, published in the Journal of Addiction Medicine, ASAM's flagship journal, note that doses should be optimal based on the individual needs of the patient. This was never in question within medical circles, including ASAM, but insurance policies and the tyranny of what is expected have led to suboptimal doses, both in the induction phase and the maintenance phase, of treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
